

Antonio Cortese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7565334/publications.pdf>

Version: 2024-02-01

20
papers

439
citations

759055

12
h-index

752573

20
g-index

20
all docs

20
docs citations

20
times ranked

968
citing authors

#	ARTICLE	IF	CITATIONS
1	A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis. <i>Neurology</i> , 2016, 86, 2094-2099.	1.5	79
2	Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis. <i>Journal of Neurology</i> , 2017, 264, 284-294.	1.8	44
3	Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study. <i>CNS Drugs</i> , 2018, 32, 963-970.	2.7	35
4	Fingolimod vs dimethyl fumarate in multiple sclerosis. <i>Neurology</i> , 2018, 91, e153-e161.	1.5	35
5	Increased Circulating Levels of Vitamin D Binding Protein in MS Patients. <i>Toxins</i> , 2015, 7, 129-137.	1.5	34
6	Duloxetine for the Treatment of Overactive Bladder Syndrome in Multiple Sclerosis. <i>Clinical Neuropharmacology</i> , 2012, 35, 231-234.	0.2	28
7	Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess atrophy in subcortical regions. <i>NeuroImage: Clinical</i> , 2017, 13, 9-15.	1.4	25
8	The prevalence of multiple sclerosis in central Italy. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1432-1436.	1.4	22
9	Attention-related changes in short-term cortical plasticity help to explain fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1359-1366.	1.4	22
10	Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers. <i>Journal of Neurology</i> , 2021, 268, 3626-3645.	1.8	16
11	Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 193-195.	0.9	14
12	CCL2 induction by 1,25(OH)2D3 in dendritic cells from healthy donors and multiple sclerosis patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 144, 102-105.	1.2	12
13	Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients. <i>Scientific Reports</i> , 2019, 9, 311.	1.6	12
14	Deep grey matter involvement and altered sensory gating in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 786-794.	1.4	12
15	Cortical M1 plasticity and metaplasticity in patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101494.	0.9	12
16	Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1272-1278.	0.9	10
17	JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	9
18	Photophobia in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 55-57.	0.9	7

#	ARTICLE	IF	CITATIONS
19	The influence of physiotherapy intervention on patients with multiple sclerosisâ€™related spasticity treated with nabiximols (THC:CBD oromucosal spray). PLoS ONE, 2019, 14, e0219670.	1.1	7
20	The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis. Neuroepidemiology, 2018, 50, 105-110.	1.1	4